SOCS proteins, cytokine signalling and immune regulation

Nature Reviews Immunology

Volumn 7, Issue 6, 2007, Pages 454-465

  Yoshimura, Akihiko ^a   Naka, Tetsuji ^b   Kubo, Masato ^c  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^c RIKEN Center for Integrative Medical Sciences   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY RNA; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 12; INTERLEUKIN 4; SMALL INTERFERING RNA; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BINDING SITE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; DENDRITIC CELL; DRUG MECHANISM; DRUG POTENCY; EXPERIMENTAL MOUSE; FATTY LIVER; GENE DELETION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; IMMUNOREGULATION; INFLAMMATORY DISEASE; INNATE IMMUNITY; INSULIN ALLERGY; MACROPHAGE; MOLECULAR BIOLOGY; MOUSE STRAIN; NATURAL KILLER CELL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SEPTIC SHOCK; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; CELL DIFFERENTIATION; CYTOKINES; DENDRITIC CELLS; HUMANS; MACROPHAGE ACTIVATION; MACROPHAGES; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; T-LYMPHOCYTES;

EID: 34249660614     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2093     Document Type: Review

References (112)

1. Nicola, N. A. Guidebook to Cytokines and Their Receptors (Oxford University Press, Oxford, 1994).
2. O'Shea, J. J., Gadina, M. & Schreiber, R. D. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109, 121-131 (2002).
3. Naka, T., Fujimoto, M., Tsutsui, H. & Yoshimura, A. Regulation of cytokine and TLR signalings by SOCS and others. Adv. Immunol. 87, 61-122 (2005). This is a comprehensive review on the regulation of cytokine signalling and TLR signalling.
4. Ilangumaran, S., Ramanathan, S. & Rottapel, R. Regulation of the immune system by SOCS family adaptor proteins. Semin. Immunol. 16, 351-365 (2004).
5. Davey, G. M., Heath, W. R. & Starr, R. SOCS1: a potent and multifaceted regulator of cytokines and cell-mediated inflammation. Tissue Antigens 67, 1-9 (2006).
6. Fletcher, J. & Starr, R. The role of suppressors of cytokine signalling in thymopoiesis and T cell activation. Int. J. Biochem. Cell Biol. 37, 1774-1786 (2005).
7. Kubo, M., Hanada, T. & Yoshimura, A. Suppressors of cytokine signaling and immunity. Nature Immunol. 4, 1169-1176 (2003). This is a review on the regulation of immunity by SOCS proteins.
8. Kamura, T. et al. VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes Dev. 18, 3055-3065 (2004).
9. Vuong, B. Q. et al. SOCS-1 localizes to the microtubule organizing complex-associated 20S proteasome. Mol. Cell. Biol. 24, 9092-9101 (2004).
10. Flowers, L. O. et al. Characterization of a peptide inhibitor of Janus kinase 2 that mimics suppressor of cytokine signaling 1 function. J. Immunol. 172, 7510-7518 (2004).
11. Waiboci, L. W. et al. Both the suppressor of cytokine signaling 1 (SOCS-1) kinase inhibitory region and SOCS-1 mimetic bind to JAK2 autophosphorylation site: implications for the development of a SOCS-1 antagonist. J. Immunol. 178, 5058-5068 (2007).
12. Bullock, A. N., Debreczeni, J. E., Edwards, A. M., Sundstrom, M. & Knapp, S. Crystal structure of the SOCS2-elongin C-elongin B complex defines a prototypical SOCS box ubiquitin ligase. Proc. Natl Acad. Sci. USA. 103, 7637-7642 (2006).
13. Bergamin, E., Wu, J. & Hubbard, S. R. Structural basis for phosphotyrosine recognition by suppressor of cytokine signaling-3. Structure 14, 1285-1292 (2006).
14. Babon, J. J. et al. The structure of SOCS3 reveals the basis of the extended SH2 domain function and identifies an unstructured insertion that regulates stability. Mol. Cell 22, 205-216 (2006).
15. Sasaki, A. et al. The N-terminal truncated isoform of SOCS3 translated from an alternative initiation AUG codon under stress conditions is stable due to the lack of a major ubiquitination site, Lys-6. J. Biol. Chem. 278, 2432-2436 (2003).
16. Chen, X. P. et al. Pim serine/threonine kinases regulate the stability of Socs-1 protein. Proc. Natl Acad. Sci. USA. 99, 2175-2180 (2002).
17. Peltola, K. J. et al. Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3. Blood 103, 3744-3750 (2004).
18. Fenner, J. E. et al. Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nature Immunol. 7, 33-39 (2006).
19. Qing, Y., Costa-Pereira, A. P., Watling, D. & Stark, G. R. Role of tyrosine 441 of interferon-γ receptor subunit 1 in SOCS-1-mediated attenuation of STAT1 activation. J. Biol. Chem. 280, 1849-1853 (2005).
20. Sasaki, A. et al. Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells 4, 339-351 (1999).
21. Machado, F. S. et al. Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nature Med. 12, 330-334 (2006).
22. Nakagawa, R. et al. SOCS-1 participates in negative regulation of LPS responses. Immunity 17, 677-687 (2002).
23. Kinjyo, I. et al. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity 17, 583-591 (2002).
24. Car, B. D. et al. Interferon γ receptor deficient mice are resistant to endotoxic shock. J. Exp. Med. 179, 1437-1444 (1994).
25. H1 cell-type immune responses by dendritic cells lacking the suppressor of cytokine signaling-1 gene. J. Immunol. 174, 4325-4332 (2005). This is the first paper showing that SOCS1-deficient DCs have the potential to induce TH1-cell differentiation.
26. Chinen, T., et al. Suppressor of cytokine signaling-1 regulates inflammatory bowel disease in which both IFNγ and IL-4 are involved. Gastroenterology 130, 373-388 (2006). This paper shows that Socs1 and Tcra double-knockout mice develop severe colitis, which is dependent on the NF-κB and JAK-STAT pathways.
27. Gingras, S., Parganas, E., de Pauw, A., Ihle, J. N. & Murray, P. J. Re-examination of the role of suppressor of cytokine signaling 1 (SOCS1) in the regulation of toll-like receptor signaling. J. Biol. Chem. 279, 54702-54707 (2004).
28. Ryo, A. et al. Regulation of NF-κB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol. Cell 12, 1413-1422 (2003).
29. Mansell, A., et al. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nature Immunol. 7, 148-155 (2006). This report is the first to show that SOCS1 binds to MAL and regulates the phosphorylation of the NF-κB subunit p65.
30. He, Y., Zhang, W., Zhang, R., Zhang, H. & Min, W. SOCS1 inhibits tumor necrosis factor-induced activation of ASK1-JNK inflammatory signaling by mediating ASK1 degradation. J. Biol. Chem. 281, 5559-5566 (2006).
31. Baetz, A., Frey, M., Heeg, K. & Dalpke, A. H. Suppressor of cytokine signaling (SOCS) proteins indirectly regulate toll-like receptor signaling in innate immune cells. J. Biol. Chem. 279, 54708-54715 (2004).
32. Qin, H., Wilson C. A., Lee, S. J. & Benveniste, E. N. IFN-β-induced SOCS-1 negatively regulates CD40 gene expression in macrophages and microglia. FASEB J. 20, 985-987 (2006).
33. Kimura, A. et al. Suppressor of cytokine signaling-1 selectively inhibits LPS-induced IL-6 production by regulating JAK-STAT. Proc. Natl Acad. Sci. USA. 102, 17089-17094 (2005).
34. Rakoff-Nahoum, S., Hao, L. & Medzhitov, R. Role of Toll-like receptors in spontaneous commensal-dependent colitis. Immunity 25, 319-329 (2006). This paper shows a differential role of innate immune recognition by TLRs in the development of commensal-dependent colitis.
35. Hanada, T., et al. IFNγ-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J. Exp. Med. 203, 1391-1397 (2006).
36. Bhan, A. K., Mizoguchi, E., Smith, R. N. & Mizoguchi, A. Colitis in transgenic and knockout animals as models of human inflammatory bowel disease. Immunol. Rev. 169, 195-207 (1999).
37. Yasukawa, H. et al. Yoshimura, A. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nature Immunol. 4, 551-556 (2003). This study is the first to show that SOCS3 determines the differences in function between IL-6 and IL-10. In addition, this study showed that sustained STAT3 activation is important for the suppression of LPS signals.
38. El Kasmi, K. C. et al. General nature of the STAT3-activated anti-inflammatory response. J. Immunol. 177, 7880-7888 (2006).
39. Murray, P. J. The JAK-STAT signaling pathway: input and output integration. J. Immunol. 178, 2623-2629 (2007).
40. Williams, L. M. et al. Expression of constitutively active STAT3 can replicate the cytokine-suppressive activity of interleukin-10 in human primary macrophages. J. Biol. Chem. 282, 6965-6975 (2007).
41. Nishinakamura, H. et al. An RNA-binding protein ?CP-1 is involved in the STAT3-mediated suppression of NF-κB transcriptional activity. Int. Immunol. 19, 609-619 (2007).
42. Butcher, B. A. et al. IL-10-independent STAT3 activation by Toxoplasma gondii mediates suppression of IL-12 and TNF-α in host macrophages. J. Immunol. 174, 3148-3152 (2005).
43. Saeij, J. P. et al.Toxoplasma co-opts host gene expression by injection of a polymorphic kinase homologue. Nature 445, 324-327 (2007). Reference 43 indicates that constitutive STAT3 activation by T. gondii infection is a mechanism of suppression of host inflammatory responses.
44. de Jonge, W. J. et al. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nature Immunol. 6, 844-851 (2005).
45. Wang, T. et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nature Med. 10, 48-54 (2004).
46. Ogata, H. et al. Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-β1 production. Oncogene 25, 2520-2530 (2006).
47. Niwa, Y. et al. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 24, 6406-6417 (2006).
48. Cheon, H. et al. Prostaglandin E2 augments IL-10 signaling and function. J. Immunol. 177, 1092-1100 (2006).
49. Prele, C. M., Keith-Magee, A. L., Yerkovich, S. T., Murcha, M. & Hart, P. H. Suppressor of cytokine signalling-3 at pathological levels does not regulate lipopolysaccharide or interleukin-10 control of tumour necrosis factor-α production by human monocytes. Immunology 119, 8-17 (2006).
50. Qin, H. et al. IL-10 inhibits lipopolysaccharide-induced CD40 gene expression through Induction of suppressor of cytokine signaling-3. J. Immunol. 177, 7761-7771 (2006).
51. Qasimi, P. et al. Divergent mechanisms utilized by SOCS3 to mediate interleukin-10 inhibition of tumor necrosis factor α and nitric oxide production by macrophages. J. Biol. Chem. 281, 6316-6324 (2006).
52. Frobose, H. et al. Suppressor of cytokine signaling-3 inhibits interleukin-1 signaling by targeting the TRAF-6/TAK1 complex. Mol. Endocrinol. 20, 1587-1596 (2006).
53. Bartz, H., Avalos, N. M., Baetz, A., Heeg, K. & Dalpke, A. H. Involvement of suppressors of cytokine signaling in toll-like receptor-mediated block of dendritic cell differentiation. Blood 108, 4102-4108 (2006).
54. Jackson, S. H., Yu, C. R., Mahdi, R. M., Ebong, S. & Egwuagu, C. E. Dendritic cell maturation requires STAT1 and is under feedback regulation by suppressors of cytokine signaling. J. Immunol. 172, 2307-2315 (2004).
55. + dendritic cell subset. Int. Immunol. 17, 1167-1178 (2005).
56. Hanada, T. et al. Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity 19, 437-450 (2003). This study shows that SOCS1-deficient DCs efficiently stimulate B-cell proliferation in vitro and autoantibody production in vivo, and concludes that SOCS1 has an essential role in DC functions and in the suppression of systemic autoimmunity.
57. Shen, L., Evel-Kabler, K., Strube, R. & Chen, S. Y. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nature Biotechnol. 22, 1546-1553 (2004). This is the first report showing that knockdown of Socs1 in DCs is useful for the induction of strong antitumour immunity.
58. Song, X. T. et al. An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Med. 3, 11 (2006).
59. Evel-Kabler, K., Song, X. T., Aldrich, M., Huang, X. F. & Chen, S. Y. SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J. Clin. Invest. 116, 90-100 (2006).
60. Li, Y., Chu, N., Rostami, A. & Zhang, G. X. Dendritic cells transduced with SOCS-3 exhibit a tolerogenic/DC2 phenotype that directs type 2 Th cell differentiation in vitro and in vivo. J. Immunol. 177, 1679-1688 (2006).
61. + T cells, respectively.
62. Flodstrom, M. et al. Target cell defense prevents the development of diabetes after viral infection. Nature Immunol. 3, 373-382 (2002).
63. Yasukawa, H. et al. The suppressor of cytokine signaling-1 (SOCS1) is a novel therapeutic target for enterovirus-induced cardiac injury. J. Clin. Invest. 111, 469-478 (2003).
64. Bullen, D V. et al. The lack of suppressor of cytokine signalling-1 (SOCS1) protects mice from the development of cerebral malaria caused by Plasmodium berghei ANKA. Parasite Immunol. 25, 113-118 (2003).
65. Zimmermann, S., Murray, P. J., Heeg, K. & Dalpke, A. H. Induction of suppressor of cytokine signaling-1 by Toxoplasma gondii contributes to immune evasion in macrophages by blocking IFN-γ signaling. J. Immunol. 176, 1840-1847 (2006). This is an interesting report showing that SOCS1 induction by T. gondii is a strategy to escape from the action of IFNs.
66. Yajima, T. et al. Innate defense mechanism against virus infection within the cardiac myocyte requiring gp130-STAT3 signaling. Circulation 114, 2364-2373 (2006). This is the first report suggesting a protective role of STAT3 in virus infection.
67. Yu, Q., Park, J. H., Doan, L. L., Erman, B., Feigenbaum, L. & Singer, A. Cytokine signal transduction is suppressed in preselection double-positive thymocytes and restored by positive selection. J. Exp. Med. 203, 165-175 (2006).
68. + T-cell lineage by preventing the harmful effects of inflammatory cytokines.
69. + T cell differentiation. Immunity 18, 475-487 (2003).
70. Cornish, AL. et al. Suppressor of cytokine signaling-1 has IFN-γ-independent actions in T cell homeostasis. J. Immunol. 170, 878-886 (2003).
71. Ramanathan, S., Gagnon, J., Leblanc, C., Rottapel, R. & Ilangumaran, S. Suppressor of cytokine signaling 1 stringently regulates distinct functions of IL-7 and IL-15 in vivo during T lymphocyte development and homeostasis. J. Immunol. 176, 4029-4041 (2006).
72. high memory T lymphocytes. J. Immunol. 171, 2435-2445 (2003).
73. Davey, G. M. et al. SOCS-1 regulates IL-15-driven homeostatic proliferation of antigen-naive CD8 T cells, limiting their autoimmune potential. J. Exp. Med. 202, 1099-1108 (2005).
74. H polarization in vivo. Int. Immunol. 14, 1343-1350 (2002).
75. Egwuagu, C. E. et al. Suppressors of cytokine signaling proteins are differentially expressed in Th1 and Th2 cells: implications for Th cell lineage commitment and maintenance. J. Immunol. 168, 3181-3187 (2002).
76. H2 cells, as well as a link between SOCS3 and human allergic diseases.
77. Yamamoto, K., Yamaguchi, M., Miyasaka, N. & Miura, O. SOCS-3 inhibits IL-12-induced STAT4 activation by binding through its SH2 domain to the STAT4 docking site in the IL-12 receptor β2 subunit. Biochem. Biophys. Res. Commun. 310, 1188-1193 (2003).
78. Takatori, H. et al. Stat5α inhibits IL-12-induced Th1 cell differentiation through the induction of suppressor of cytokine signaling 3 expression. J. Immunol. 174, 4105-4112 (2005).
79. Ozaki, A., Seki, Y., Fukushima, A. & Kubo, M. The control of allergic conjunctivitis by suppressor of cytokine signaling (SOCS)3 and SOCS5 in a murine model. J. Immunol. 175, 5489-5497 (2005).
80. H17 cells cross-regulate each other.
81. Harada, M., et al. Functional polymorphism in the suppressor of cytokine signaling 1 gene associated with adult asthma. Am. J. Respir. Cell Mol. Biol. 36, 491-496 (2006).
82. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature Immunol. 6, 1123-1132 (2005).
83. + T helper cells. Cell 126, 1121-1133 (2006).
84. H17-cell differentiation.
85. Wong, K. et al. SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. J. Clin. Invest. 116, 1571-1581 (2006).
86. Stumhofer, J. S. et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nature Immunol. 7, 937-945 (2006).
87. + T cells partially through STAT3-dependent mechanism. J. Immunol. 177, 5377-5385 (2006).
88. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med. 198, 1875-1886 (2003).
89. Roncarolo, M. G. et al. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev. 212, 28-50 (2006).
90. Nagaki-Ohara, K. et al. Suppressor of cytokine signalling 1 in lymphocytes regulates the development of intestinal inflammation in mice. Gut 55, 212-219 (2006).
91. Kasprzycka, M., Marzec, M., Liu, X., Zhang, Q. & Wasik, M. A. Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc. Natl Acad. Sci. USA. 103, 9964-9969 (2006).
92. H17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24, 677-688 (2006).
93. Weniger, M. A. et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 25, 2679-2684 (2006).
94. Melzner, I. et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood 105, 2535-2542 (2005). This is the first report showing the presence of SOCS1 mutations in lymphomas.
95. Limnander, A., Danial, N. N. & Rothman, P. B. v-Abl signaling disrupts SOCS-1 function in transformed pre-B cells. Mol. Cell 15, 329-341 (2004).
96. Jost, E., et al. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. Leukemia 21, 505-510 (2007).
97. Yoshikawa, H. et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nature Genet. 28, 29-35 (2001). This is the first report showing silencing of SOCS1 gene expression in human HCC.
98. Yoshimura, A. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci. 97, 439-447 (2006).
99. Yang, B., Guo, M., Herman, J. G. & Clark, D. P. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am. J. Pathol. 163, 1101-1107 (2003).
100. Yoshida, T. et al. SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. J. Exp. Med. 199, 1701-1707 (2004). This paper shows that SOCS1 is an anti-oncogene of HCC by suppressing liver inflammation.
101. Ogata, H. et al. Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology 131, 179-193 (2006).
102. Huang, Y., et al. Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology 132, 733-744 (2007).
103. Shouda, T. et al. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J. Clin. Invest. 108, 1781-1788 (2001).
104. Jo, D., Liu, D., Yao, S., Collins, R. D. & Hawiger, J. Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis. Nature Med. 11, 892-898 (2005).
105. Mujtaba, M. G. et al. Treatment of mice with the suppressor of cytokine signaling-1 mimetic peptide, tyrosine kinase inhibitor peptide, prevents development of the acute form of experimental allergic encephalomyelitis and induces stable remission in the chronic relapsing/remitting form. J. Immunol. 175, 5077-5086 (2005).
106. Flowers, L. O., Subramaniam, P. S., Johnson, H. M. A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells. Oncogene 24, 2114-2120 (2005).
107. Yang, R. et al. Single-walled carbon nanotubes-mediated in vivo and in vitro delivery of siRNA into antigen-presenting cells. Gene Ther. 13, 1714-1723 (2006).
108. Ueki, K., Kadowaki, T. & Kahn, C. R. Role of suppressors of cytokine signaling SOCS-1 and SOCS-3 in hepatic steatosis and the metabolic syndrome. Hepatol. Res. 33, 185-192 (2005).
109. Yamada, S., Shiono, S., Joo, A. & Yoshimura, A. Control mechanism of JAK/STAT signal transduction pathway. FEBS Lett. 534, 190-196 (2003). This is the first report of a computer simulation model for the JAK-STAT-SOCS pathway.
110. Yamada, S., Tsukada, J., Yoshimura, A. & Kubo, M. Computer simulation of the role of SOCS family protein in helper T cell differentiation. Int. Immunol. 18, 335-345 (2006).
111. Mendoza, L. A network model for the control of the differentiation process in Th cells. Biosystems 84, 101-114 (2006).
112. Qiao, X. et al. Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nature Immunol. 7, 302-310 (2006).